# Why Test Type Matters
A TP53 result means very little without knowing which test produced it.
The phrase **"TP53 mutation"** is not enough on its own. The test type tells you where the finding came from, and the variant type tells you what it may mean biologically.
These details change everything:
* whether the result is inherited or tumour-acquired
* whether it changes chemotherapy or radiation treatment planning
* whether it matters for family risk
* whether it helps answer tumour-behaviour questions such as the fenbendazole or NAC question
### Start with the first two questions
Before interpreting any TP53 result, ask:
1. **Is this from a cancer biopsy (somatic) test, or from a SNP variant report, or a germline test?**
2. **Is there a specific variant code listed next to TP53?**
Without considering the source of the test result, people often talk as if they are discussing the same thing when they are not.
***
### The three main TP53 results are being thrown around in the online support groups.
There are three distinct TP53 testing contexts; many cancer centres use two of them, and many patients use the first independently.
#### SNP or nutrigenomic testing
This usually comes from a lifestyle, wellness, or nutrigenomic report rather than from an oncology lab.
It looks at **common inherited variants** in TP53, most often `rs1042522`, rather than rare pathogenic mutations.
These findings are **not** the same as a tumour mutation, and they are **not** the same as a clinical germline TP53 result.
This type of report is usually trying to answer questions like:
* how well supported baseline p53 function may be in healthy cells
* whether there may be higher support needs around DNA repair, oxidative stress, or toxin exposure
* whether the surrounding genes in the same report change the practical picture
This is the most actionable TP53 layer from a nutrition and lifestyle angle, but it is also the easiest one to overread.
It can point to **support needs**. It does **not** diagnose Li-Fraumeni syndrome, nor does it tell you what the tumour has done to TP53.
**Read more:** [TP53 SNPs and Nutrigenomics](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-snps-and-nutrigenomics.md)
***
#### Germline or hereditary testing
This tests blood, saliva, or another constitutional sample for DNA you were born with.
These variants are present in most or all cells of the body and may be inherited or passed on.
A germline TP53 finding is a completely different conversation from a somatic tumour TP53 finding.
It can affect:
* inherited cancer-risk interpretation
* family implications
* surveillance planning
* treatment-planning decisions, especially around radiotherapy and genotoxic chemotherapy
* **Read more:** [Germline TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/germline-tp53.md)
***
#### Somatic or tumour testing
This tests tumour tissue or tumour-derived DNA to find mutations that developed inside the cancer cells.
These mutations are **not inherited**. They exist in the tumour, not across the rest of the body.
**This is the tumor mutation referred to as the somatic p53 mutation. It the is most common TP53 result discussed in oncology. Somatic TP53 findings are seen in a large share of cancers.**
Typical examples include:
* tumour NGS panels
* broad genomic profiling from a tumour biopsy
* liquid-biopsy tumour profiling
* reports with variant codes such as `p.R175H` or `c.524G>A`
This is the result type that most directly answers:
* does the tumour still have **functional p53**?
* is there a **stable yet harmful mutant** protein?
* is the tumour effectively **p53-null**?
**Read more:** [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md)
***
### How does this distinction change treatment planning?
If the TP53 result you have been given is **germline**, the question is no longer just what the tumour is doing.
The question becomes whether the person carries a heritable TP53-related cancer-risk syndrome and whether **some standard treatments may carry disproportionate long-term harm**.
Guideline-based sources emphasise that germline TP53 status should be known early enough to inform treatment planning, where clinically relevant.
{% hint style="warning" %}
If a TP53 finding came from a germline panel and was never clearly discussed between genetics and oncology, that gap needs to be followed up.
{% endhint %}
### Germline blueprint and tumour behaviour are not the same thing
Even when someone carries a **germline TP53** pathogenic variant, it does not fully tell you what the tumour has done to TP53.
In many germline mutation settings, healthy cells still retain one working copy. That is the usual heterozygous state.
For much of the body, that remaining copy may still provide meaningful function.
### The tumour is a separate problem.
As cancer cells divide and accumulate damage, the remaining functional TP53 copy may later be lost or damaged inside the tumour itself.
That is the **loss-of-heterozygosity** question.
When that happens, the tumour may end up with little or no functional p53 even though the person began with one working copy in healthy tissue.
This is why two separate questions can both matter:
* the **inherited blueprint**
* the tumour's **final p53 status**
### Why the exact variant code still matters
Once the test type is clarified, the next layer is the actual variant.
That determines whether:
* some p53 function may remain
* a stable mutant protein is accumulating
* the protein is absent altogether
* mutation-specific strategy questions make any biological sense
Use [TP53 Mutation Types Reference](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53/tp53-mutation-types-reference.md) when a report includes a code such as `p.R175H`, `p.R248Q`, `p.P128fs`, or a splice-site notation.
### The practical split
The most useful shortcut is:
* **If it is a SNP or nutrigenomic result** → the next question is what the report is saying about baseline support needs, and whether surrounding repair genes change the picture
* **If it is a germline result** → the next question is whether the tumour also lost its remaining functional TP53 biology
* **If it is a somatic tumour result** → the next question is what mutation class the tumour has now
That is why SNP, germline, and somatic testing are complementary rather than interchangeable.
### What may already be in your records
Before assuming the answer is unknown, check for:
* hereditary cancer panels
* prior BRCA-focused genetics reports that may have included TP53
* tumour NGS reports
* liquid-biopsy reports
* pathology wording about `p53 null`, `p53 overexpression`, or aberrant staining
Some people already have the key answer buried in existing records.
### Why this distinction mean for the fenbendazole question
The fenbendazole question is mainly a **tumour biology** question.
What matters most there is what the tumour is doing with p53 now. So we are looking at somatic p53 mutations.
The most direct page to read about that issue is [Fenbendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/fenbendazole-and-tp53.md).
The short version is:
* fenbendazole appears more favourable when tumour p53 is still functional
* that advantage is weakened in mutant or null p53 tumour states
So a SNP report or germline TP53 result does not settle the Fenbendazole question. **Read more:** [Fenbendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/fenbendazole-and-tp53.md).
### The core message
We are not dealing with one TP53 story.
We are dealing with at least three layers:
* common SNP-level variation
* rare inherited germline pathogenic variants
* tumour-acquired somatic mutations
If the test type is unclear, the interpretation will usually be wrong or incomplete.
### Three Statements That Counter The "We'll See How You Respond" Response
Patient-facing wording you can bring into the appointment, so when they say....
**"TP53 testing isn't standard for your cancer type"**\
ASCO's 2024 guidelines state all patients with tumour variants in TP53 should be offered germline testing, and universal germline testing is now being recommended across cancer types because guideline-directed testing misses over 50% of actionable variants
**'We'll know if treatment works by your response"**\
Radiation-induced secondary cancers in Individuals with germline **TP53** mutations appear years later — by then the damage is done. We cannot undo radiotherapy."[ pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880795/)
**"Your family history doesn't suggest Li-Fraumeni"**\
A 2025 study confirmed that over 61% of germline TP53 carriers do not meet the traditional Chompret criteria — so family history alone is no longer a reliable filter for who should be tested."[ pubmed.ncbi.nlm.nih](https://pubmed.ncbi.nlm.nih.gov/39962599/)
### If the issue is suspected germline TP53
Why do some patients push harder for testing before treatment
There is a strong case for this:
* some guidelines explicitly emphasise knowing TP53 status before treatment where heritable TP53 is a realistic concern
* radiotherapy and genotoxic chemotherapy may carry disproportionate long-term harm in germline TP53 carriers
* family history alone misses a meaningful share of carriers
That is why some patients frame germline TP53 testing not as an optional extra, but as part of informed treatment planning when the clinical context justifies it.
### Australia-specific note
Australian services and guideline references
For Australian readers, eviQ is a legitimate national reference point for TP53-related risk-management pathways.
Specialist familial-cancer services, including Peter MacCallum's familial cancer service, may be relevant when a germline TP53 question has not been fully integrated into treatment planning.
### Where to go next
* Use [TP53 SNPs and Nutrigenomics](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-snps-and-nutrigenomics.md) if your result came from a nutrigenomic or lifestyle report, or if the question is about common SNP-level support needs.
* Use [Germline TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/germline-tp53.md) for inherited high-impact findings.
* Use [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md) for the tumour-acquired layer.
* Use [Questions for Oncologists](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/questions-for-oncologists.md) for practical clinic wording.
### Key references
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes\
Dogra et al. Scientific Reports fenbendazole study\
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/why-test-type-matters.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.